Drugs News and Research

RSS

UCSD selects Millennium Labs, Research Institute for NIAAA granted study

Millennium Laboratories, a leading provider of therapeutic drug monitoring, research and healthcare education, and the Millennium Research Institute, a national non-profit research center, announced today they have been selected by the University of California, San Diego School of Medicine to provide laboratory services, including research and analysis, for a new UC San Diego study funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

22 Mar 2011

CTC counting can determine lung cancer aggressiveness, predict best treatment

CANCER RESEARCH UK scientists have found that counting the number of lung cancer cells circulating in the blood could determine how aggressive the cancer is and predict the best treatment to use.

22 Mar 2011

Rethink acknowledges Ontario's new breast cancer program

Rethink Breast Cancer acknowledges today's swift decision by the Ontario government to take steps towards providing greater access to specific cancer treatments.

22 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

PSN system can reduce psychiatric medication errors

Coupling an electronic prescription drug ordering system with a computerized method for reporting adverse events can dramatically reduce the number of medication errors in a hospital's psychiatric unit, suggests new Johns Hopkins research.

22 Mar 2011

ACE, ARB combination therapy may increase risk of kidney failure, death

Elderly patients prescribed combination angiotensin converting enzyme inhibitors and angiotensin receptor blockers had a higher risk of kidney failure and death, according to a study published in CMAJ.

22 Mar 2011

City Of Hope opens new center for diabetes research and care

City of Hope has established a new Diabetes Research Center that will expand its pioneering investigations into diabetes, endocrinology and metabolic diseases, create an infrastructure to support translational research and enhance clinical care for diabetes and its related complications.

22 Mar 2011

Information technology could reduce psychiatric drug errors

21 Mar 2011

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Insmed Incorporated, a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

Researchers baffled with increase in migraine rates

Migraine rates in a comprehensive Norwegian health study have climbed by 1% in a decade -- that may not sound like much, but in the Norwegian context, it means 45,000 more migraine sufferers -- and if the trend were to hold for the European Union, that would be an additional 5 million more people plagued by migraines. Researchers at the Norwegian University of Science and Technology (NTNU) are baffled by the cause of this trend.

21 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Drugs News and Research

UCSD selects Millennium Labs, Research Institute for NIAAA granted study

CTC counting can determine lung cancer aggressiveness, predict best treatment

Rethink acknowledges Ontario's new breast cancer program

Study: Stem cell transplant may benefit patients with rapidly progressive MS

PSN system can reduce psychiatric medication errors

ACE, ARB combination therapy may increase risk of kidney failure, death

City Of Hope opens new center for diabetes research and care

Information technology could reduce psychiatric drug errors

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

Sarsia Seed provides follow-up funding for APIM Therapeutics

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

Physical ill-health reduces life expectancy of people with severe mental illness

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

Researchers baffled with increase in migraine rates

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News